Cetuximab
Colorectal Carcinoma
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Shanghai Changzheng Hospital
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06603376CT.gov Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer | — | Recruiting | — | — | — |
NCT06640166CT.gov Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. | — | Recruiting | — | — | — |
NCT05863195CT.gov Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | — | Recruiting | — | — | — |
NCT05786924CT.gov Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies | — | Recruiting | — | — | — |
NCT05358249CT.gov Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT05200442CT.gov A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | — | Suspended | — | — | — |
NCT04616183CT.gov LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
NCT04673955CT.gov BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment | — | Recruiting | — | — | — |
NCT03366155CT.gov Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | — | Completed | — | — | — |
NCT04017650CT.gov Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | — | Active Not Recruiting | — | — | — |
Show 10 more trialsShow fewer
NCT03290937CT.gov Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT02713373CT.gov Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT02563002CT.gov Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | — | Completed | — | — | — |
NCT01252628CT.gov Phase 1 and 2 Study of PX-866 and Cetuximab | — | Completed | — | — | — |
NCT00545545CT.gov Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma | — | Completed | — | — | — |
NCT00478634CT.gov A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | — | Completed | — | — | — |
NCT00437268CT.gov A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer | — | Completed | — | — | — |
NCT00361244CT.gov SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | — | Terminated | — | — | — |
NCT00362102CT.gov A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma | — | Completed | — | — | — |
NCT00215722CT.gov XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cetuximab (this asset) | Shanghai Changzheng Hospital | P3 | BB · 64 |
| Tipiracil | Mayo Clinic | P2 | BBB |
| Fluorouracilum | City of Hope Medical Center | P4 | BB |
| Oxaliplatin | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Muamycin | City of Hope Medical Center | P3 | BB |
| Capecitabine | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Pentoxifylline | Tanta University | P4 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P3 | BB |
+42 more in the Colorectal Carcinoma cohort
Other indications for Cetuximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colon Adenocarcinoma | — | P3 | BB · 70 |
| Rectal Carcinoma | — | P2 | BB · 69 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Cetuximab in Colorectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/cetuximab-colorectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →